HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses

European Journal of Immunology

Volumn 37, Issue 3, 2007, Pages 675-685

  Kmieciak, Maciej ^a   Knutson, Keith L ^b   Dumur, Catherine I ^a   Manjili, Masoud H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Cytokines; Immune evasion; Tumor immunology

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER RECURRENCE; CANCER RELAPSE; CELL CLONING; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN TARGETING; RAT; T LYMPHOCYTE; TUMOR ESCAPE; TUMOR IMMUNITY; ANIMAL; CARCINOMA; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR RECURRENCE;

ANIMALS; CARCINOMA; CELL LINE, TUMOR; FEMALE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; NEOPLASM RECURRENCE, LOCAL; RATS; RECEPTOR, ERBB-2; T-LYMPHOCYTES;

EID: 34147101048     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200636639     Document Type: Article

References (34)

1. Maeurer, M. J., Gollin, S. M., Storkus, W. J., Swaney, W., Karbach, J., Martin, D., Castelli, C. et al., Tumor escape from immune recognition: Lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J. Clin. Invest. 1996. 98: 1633-1641.
2. Wang, Z., Marincola, F. M., Rivoltini, L., Parmiani, G. and Ferrone, S., Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MFL28 melanoma cells. J. Exp. Med. 1999. 190: 205-215.
3. Yamshchikov, G. V., Mullins, D. W., Chang, C. C., Ogino, T., Thompson, L., Presley, J., Galavotti, H. et al., Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J. Immunol. 2005. 174: 6863-6871.
4. Facoetti, A., Nano, R., Zelini, P., Morbini, P., Benericetti, E., Ceroni, M., Campoli, M. and Ferrone, S., Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin. Cancer Res. 2005. 11: 8304-8311.
5. Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J. and Schreiber, R. D., IFN-γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001. 410: 1107-1111.
6. Engel, A. M., Svane, I. M., Rygaard, J. and Werdelin, O., MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand. J. Immunol. 1997. 45: 463-470.
7. Svane, I. M., Engel, A. M., Nielsen, M. B., Ljunggren, H. G., Rygaard, J. and Werdelin, O., Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. Eur. J. Immunol. 1996. 26: 1844-1850.
8. Dunn, G. P., Old, L. J. and Schreiber, R. D., The three Es of cancer immunoediting. Annu. Rev. Immunol. 2004. 22: 329-360.
9. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. and Schreiber, R. D., Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol. 2002. 3: 991-998.
10. Beatty, G. L. and Paterson, Y., IFN-γ can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J. Immunol. 2000. 165; 5502-5508.
11. Beatty, G. L. and Paterson, Y., Regulation of tumor growth by IFN-γ in cancer immunotherapy. Immunol. Res. 2001. 24: 201-210.
12. Manjili, M. H., Wang, X.-Y., Chen, X., Martin, T., Repasky, E. A., Henderson, R. and Subjeck, J. R., HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J. Immunol. 2003. 171: 4054-4061.
13. Zhou, H., Chen, W. D., Qin, X., Lee, K., Liu, L., Markowitz, S. D. and Gerson, S. L., MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice. Oncogene 2001. 20: 6009-6017.
14. + T cells in patients with melanoma". J. Immunol. 2006. 176: 4511.
15. Lengauer, C., Kinzler, K. W. and Vogelstein, B., Genetic instabilities in human cancers. Nature 1998. 396: 643-649.
16. Manjili, M. H., Arnouk, H., Knutson, K. L., Kmieciak, M., Disis, M. L., Subjeck, J. R. and Kazim, A. L., Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals". Breast Cancer Res. Treat. 2006. 96: 233-241.
17. Knutson, K. L., Almand, B., Dang, Y. and Disis, M. L., Neu antigen-negative variants can be generated after neu-specific Ab therapy in neu transgenic mice. Cancer Res. 2004. 64: 1146-1151.
18. Vernimmen, D., Begon, D., Salvador, C., Gofflot, S., Grooteclaes, M. and Winkler, R., Identification of HTT (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression. Biochem. J. 2003. 370: 323-329.
19. Marth, C., Muller-Holzner, E., Greiter, E., Cronauer, M. V., Zeimet, A. G., Doppler, W., Eibl, B. et al., Gamma-interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells. Cancer Res. 1990. 50: 7037-7041.
20. Knutson, K. L., Lu, H., Stone, B., Reiman, J. M., Behrens, M. D., Prosperi, C. M., Gad, E. A. et al., Immunoediting of cancers may lead to epithelial to mesenchymal transition. J. Immunol. 2006. 177: 1526-1533.
21. Gershengorn, M. C., Hardikar, A. A., Wei, C., Geras-Raaka, E., Marcus-Samuels, B. and Raaka, B. M., Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells. Science 2004. 306: 2261-2264.
22. + T cells in patients with melanoma. J. Immunol. 2005. 175: 6169-6176.
23. Bui, J. D., Carayannopoulos, L. N., Lanier, L. L., Yokoyama, W. M. and Schreiber, R. D., IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J. Immunol. 2006. 176: 905-913.
24. Hueman, M. T., Dehqanzada, Z. A., Novak, T. E., Gurney, J. M., Woll, M. M., Ryan, G. B., Storrer, C. E. et al., Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clin. Cancer Res. 2005. 11: 7470-7479.
25. Peoples, G. E., Gurney, J. M., Hueman, M. T., Woll, M. M., Ryan, G. B., Storrer, C. E., Fisher, C. et al., Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients, J. Clin. Oncol. 2005. 23: 7536-7545.
26. Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D. and Muller, W. J., Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 1992. 89: 10578-10582.
27. Campbell, M. J., Wollish, W. S., Lobo, M. and Esserman, L. J., Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse. In Vitro Cell. Dev. Biol. Anim. 2002. 38: 326-333.
28. Eray, M., Matto, M., Kaartinen, M., Andersson, L. and Pelkonen, J., Flow cytometric analysis of apoptotic subpopulations; with a combination of annexin V-FITC, propidium iodide, and SYTO 17. Cytometry 2001. 43: 134-142.
29. Affymetrix, Affymetrix Microarray Suite User's Guide, version 5.0. Affymetrix, Santa Clara, CA 2001.
30. Sugita, M., Geraci, M., Gao, B., Powell, R. L., Hirsch, F. R., Johnson, G., Lapadat, R. et al., Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res. 2002. 62: 3971-3979.
31. Irizarry, R. A., Bolstad, B. M., Collin, F., Cope, L. M., Hobbs, B. and Speed, T. P., Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003. 31: E15.
32. Baldi, P. and Long, A. D., A Bayesian framework for the analysis of microarray expression data: Regularized t-test and statistical inferences of gene changes. Bioinformatics 2001. 17: 509-519.
33. Zhang, L., Wang, L., Ravindranathan, A. and Miles, M. F., A new algorithm for analysis of oligonucleotide arrays: Application to expression profiling in mouse brain regions. J. Mol. Biol. 2002. 317: 225-235.
34. Liu, K., Caldwell, S. A. and Abrams, S. L, Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-γ-regulated gene expression. Cancer Res. 2005. 65: 4376-4388.